Page last updated: 2024-10-15

cenderitide

Description

cenderitide: a heart drug from venom of African green mamba [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID155817506
MeSH IDM0578407

Synonyms (3)

Synonym
cd-np
cenderitide
gtpl9066

Research Excerpts

Overview

Cenderitide is a novel anti-proliferative chimeric peptide of semi-endothelial origin. It targets the particulate guanylyl cyclase B (pGC-B) receptor and pGC-A unlike native NPs.

ExcerptReference
"Cenderitide is a novel designer natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). "( A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure.
Bailey, KR; Benike, SL; Burnett, JC; Cannone, V; Chen, HH; Ichiki, T; Kawakami, R; Lee, CYW; Martin, FL; Sangaralingham, SJ; Schirger, JA; Scott, C, 2018
)
"Cenderitide is a novel designer natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). "( Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide.
Burnett, JC; Dzhoyashvili, N; Ichiki, T, 2019
)
"Cenderitide (CD-NP) is a novel antiproliferation chimeric peptide of semiendothelial origin; thus, this paper aims to demonstrate the selectivity aspect of this new peptide via in vitro evaluation on key players in ISR-smooth muscle cells (SMCs) and endothelial cells."( In vitro evaluation of cenderitide-eluting stent I -an antirestenosis and proendothelization approach.
Burnett, JC; Chen, HH; Freddy Boey, YC; Huang, Y; Lim, SG; Liu, KL; Ng, XW; Venkatraman, SS, 2014
)
"Cenderitide (CD-NP) is a novel anti-proliferative chimeric peptide of semi-endothelial origin."( In vivo Evaluation of Cenderitide-Eluting Stent (CES) II.
Boey, YC; Burnett, JC; Chen, HH; Huang, Y; Lim, SG; Ng, XW; Venkatraman, SS, 2016
)
"Cenderitide is a novel dual natriuretic peptide (NP) receptor chimeric peptide activator, which targets the particulate guanylyl cyclase B (pGC-B) receptor and pGC-A unlike native NPs. "( Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.
Burnett, JC; Huntley, BK; Ichiki, T; Lee, CY; Lisy, O; McCormick, DJ; Sangaralingham, SJ, 2016
)

Toxicity

ExcerptReference
" Four-hour infusion of Cenderitide was safe, well-tolerated, and significantly increased plasma cGMP levels and urinary cGMP excretion without adverse effects with no change in blood pressure."( A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure.
Bailey, KR; Benike, SL; Burnett, JC; Cannone, V; Chen, HH; Ichiki, T; Kawakami, R; Lee, CYW; Martin, FL; Sangaralingham, SJ; Schirger, JA; Scott, C, 2018
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1345469Human Guanylyl cyclase-B (Receptor Guanylyl Cyclase (RGC) family)2012PloS one, , Volume: 7, Issue:12
CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart.
AID1345483Human Guanylyl cyclase-A (Receptor Guanylyl Cyclase (RGC) family)2012PloS one, , Volume: 7, Issue:12
CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's14 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Reviews5 (35.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]